Shield Therapeutics Future Growth

Future criteria checks 2/6

Shield Therapeutics is forecast to grow earnings and revenue by 84.6% and 46.9% per annum respectively while EPS is expected to grow by 104.1% per annum.

Key information

84.6%

Earnings growth rate

104.1%

EPS growth rate

Pharmaceuticals earnings growth19.6%
Revenue growth rate46.9%
Future return on equityn/a
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

Recent updates

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Earnings and Revenue Growth Forecasts

AIM:STX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202672N/A-6-11
12/31/202554-8-7-41
12/31/202429-22-17-142
6/30/202421-36-23-21N/A
3/31/202417-35-32-29N/A
12/31/202313-33-40-37N/A
9/30/202310-40-35-33N/A
6/30/20237-47-30-28N/A
3/31/20236-49-28-25N/A
12/31/20225-50-25-23N/A
9/30/20225-39-27-24N/A
6/30/20224-30-31-27N/A
3/31/20223-29-29-26N/A
12/31/20212-27-27-25N/A
9/30/20212-22-21-20N/A
6/30/20213-18-16-16N/A
3/31/20219-11-9-9N/A
12/31/202014-4-2-2N/A
9/30/202013-3-1-1N/A
6/30/202011-200N/A
3/31/20206-6-4-3N/A
12/31/20191-12-7-5N/A
9/30/20198-4-11N/A
6/30/201915346N/A
3/31/201915003N/A
12/31/201815-2-40N/A
9/30/20188-13-14-9N/A
6/30/20181-24-24-19N/A
3/31/20181-26N/A-21N/A
12/31/20171-26N/A-22N/A
9/30/20171-24N/A-21N/A
6/30/20170-21N/A-19N/A
3/31/20170-19N/A-16N/A
12/31/20160-19N/A-13N/A
9/30/20160-12N/A-12N/A
6/30/20160-4N/A-10N/A
3/31/20160-19N/A-8N/A
12/31/2015N/A-35N/A-6N/A
9/30/20150-41N/A-5N/A
6/30/20150-49N/A-4N/A
3/31/20150-33N/A-5N/A
12/31/20140-20N/A-5N/A
12/31/20130-7N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STX's revenue (46.9% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: STX's revenue (46.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STX's Return on Equity is forecast to be high in 3 years time


Discover growth companies